Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.52 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613404 | 0.97 | L3MBTL1 (0.56) | KMT2AMEN1ATML3MBTL1PANK3 | |
| SCHEMBL12436381 | 0.81 | ECE2 (0.51) | KMT2AMEN1PANK3ECE2NPC1 | |
| SCHEMBL5080004 | 0.80 | PANK3 (0.49) | KMT2AMEN1ATMPANK3SMN1; SMN2 | |
| SCHEMBL14084729 | 0.78 | GABRP (0.58) | KMT2AMEN1PANK3ECE2NPC1 | |
| SCHEMBL8163504 | 0.76 | PANK3 (0.48) | KMT2AMEN1ATML3MBTL1PANK3 | |
| SCHEMBL7430480 | 0.75 | HPGD (0.67) | KMT2AMEN1ATMNPC1HPGD | |
| SCHEMBL256024 | 0.74 | GABRP (0.61) | KMT2AMEN1ATML3MBTL1NPC1 | |
| SCHEMBL30154481 | 0.74 | GABRP (0.61) | KMT2AMEN1ATML3MBTL1NPC1 | |
| SCHEMBL9528958 | 0.73 | HPGD (0.70) | KMT2AMEN1ATMNPC1HPGD | |
| SCHEMBL13195578 | 0.73 | SMN1; SMN2 (0.64) | ECE2NPC1HPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2900242-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GCGR, GPR139 | KMT2A 4493/4885MEN1 4127/4885ATM 3919/4885 |
| US-20140329798-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | GPR119, GPR27, GCGR | KMT2A 4278/4885MEN1 3858/4885ATM 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.